ArticleBMC infectious diseases2026
Clinical application and safety observation of levofloxacin in children with refractory Mycoplasma pneumoniae pneumonia.
Article in BMC infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIn recent years, Mycoplasma pneumoniae (MP) has developed widespread resistance to macrolide antibiotics, and second-line anti-Mycoplasma drugs such as levofloxacin have begun to be used in children. However, there is currently insufficient data on their efficacy and safety.
objectiveTo explore the application effect of levofloxacin in children with refractory Mycoplasma pneumoniae pneumonia (RMPP) and evaluate its safety.
methodsThis study is an exploratory research, selecting 82 RMPP patients treated with levofloxacin who were admitted to the Department of Pediatric Respiratory Medicine at Weifang People's Hospital between November 2023 and December 2024 as the research subjects. Compared the blood routine and biochemical indicators before and after the application of levofloxacin, and observed the clinical efficacy and adverse reactions of levofloxacin.
resultsThe average fever reduction time after the application of levofloxacin was (1.96 ± 1.52) days. After the application of levofloxacin, there was no change in white blood cell (WBC), neutrophil (N), platelet (PLT) and other parameters in the blood routine (P > 0.05). The lymphocyte count (L) has increased but remains within the normal range. There was no difference in alanine aminotransferase (ALT) before and after treatment, but aspartate aminotransferase (AST) decreased compared to before. Lactate dehydrogenase (LDH) and creatine kinase isoenzyme (CKMB) decreased after medication (P < 0.05), while creatine kinase (CK) remained unchanged. Blood creatinine (CREA) and Blood urea (Urea) both decreased (P < 0.05), indicating no damage to liver and kidney function. There were a total of 9 adverse drug reactions related to levofloxacin, including 5 cases of rash, 2 cases of gastrointestinal reactions, 1 case of neurological reaction, and 1 case of lower limb pain. No other adverse reactions or sequelae were observed during the 12-month clinical follow-up.
conclusionLevofloxacin has shown good efficacy in treating RMPP in children, with no serious adverse reactions detected in a short period of time.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.